GlassScriptPhysician profile
Roger J Bedimo
NPI 1508879859
$269,276.58
in general payments reported to CMS, 2019-2025
10 companies · $34K in 2025
The $34K reported for 2025 was more than what 97% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49K · 2020: $20K · 2021: $14K · 2022: $24K · 2023: $64K · 2024: $65K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $100K · Travel and Lodging: $36K · Honoraria: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,960 · Food and Beverage: $3,310 · Education: $1,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $100,143.43 |
| Travel and Lodging | $36,460.60 |
| Honoraria | $14,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,960.00 |
| Food and Beverage | $3,309.71 |
| Education | $1,885.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $88,616.54 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Merck Sharp & Dohme LLC | $68,779.38 | 2019-2025 | Isentress, Steglatro, Pifeltro |
| Gilead Sciences, INC. | $36,044.43 | 2019-2025 | Veklury, Biktarvy |
| Shionogi INC | $26,182.85 | 2022-2025 | Fetroja, S-217622 |
| Theratechnologies INC. | $19,936.27 | 2020-2025 | Egrifta Sv, Trogarzo, Egrifta |
| Emd Serono, INC. | $19,514.84 | 2023-2024 | Serostim |
| Glaxosmithkline, LLC. | $5,808.27 | 2024 | |
| Janssen Products, LP | $4,300.00 | 2022 | |
| Janssen Scientific Affairs, LLC | $94.00 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Bedimo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.